Evidence map›Paper›PMID 23580319›Full record

ReviewDrugs & aging2013

The pharmacological approach to the elderly COPD patient.

Timothy E Albertson, Michael Schivo, Amir A Zeki, Samuel Louie, Mark E Sutter, Mark Avdalovic, Andrew L Chan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs & aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2017
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Timothy E AlbertsonDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, 4150 V Street, Suite 3400, Davis, CA, USA. tealbertson@ucdavis.edu
Michael Schivo
Amir A Zeki
Samuel Louie
Mark E Sutter
Mark Avdalovic
Andrew L Chan
University of California, Davis · USVA Northern California Health Care System · US

Funding

UC Davis Clinical and Translational Science CenterKL2TR000134 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$3.1M
UC Davis Clinical and Translational Science CenterKL2RR024144 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2006 to 2011
$3.1M
The Modulation of Eotaxin Expression by Statins: Implications for Asthma TherapyK08HL114882 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2014 to 2016
$435k
NCATS NIH HHS KL2 TR000134NCRR NIH HHS KL2 RR024144NHLBI NIH HHS K08 HL114882
6 · The paper itself

Abstract

The elderly patient (65 years and older) with chronic obstructive pulmonary disease (COPD) can be a challenge to the clinician. This begins with the correct and early diagnosis, the assessment of disease severity, recognizing complicating comorbidities, determining the burden of symptoms, and monitoring the frequency of acute exacerbations. Comprehensive management of COPD in the elderly patient should improve health-related quality of life, lung function, reduce exacerbations, and promote patient compliance with treatment plans. Only smoking cessation and oxygen therapy in COPD patients with hypoxemia reduce mortality. Bronchodilators, corticosteroids, methylxanthines, phosphodiesterase-4 inhibitors, macrolide antibiotics, mucolytics, and pulmonary rehabilitation improve some outcome measures such as spirometry measures and the frequency of COPD exacerbations without improving mortality. International treatment guidelines to reduce symptoms and reduce the risk of acute exacerbations exist. Relief of dyspnea and control of anxiety are important. The approach to each patient is best individualized. Earlier use of palliative care should be considered when traditional pharmacotherapy fails to achieve outcome measures and before consideration of end-of-life issues.

Indexed as

AgedAge FactorsBronchodilator AgentsDisease ManagementHumansOxygen Inhalation TherapyPalliative CarePractice Guidelines as TopicPulmonary Disease, Chronic ObstructiveSmoking CessationVaccinationBronchodilator Agents

Identifiers

PMID23580319
OpenAlexW2011756745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.